Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for SUPN

Stock Name	Supernus Pharmaceuticals Inc
Ticker	SUPN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US8684591089
LEI	549300GRM36VBKISYJ58

Show aggregate SUPN holdings

News associated with SUPN

Contrasting Supernus Pharmaceuticals (NASDAQ:SUPN) and Evoke Pharma (NASDAQ:EVOK): Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) and Evoke Pharma (NASDAQ:EVOK – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Volatility & Risk Supernus Pharmaceuticals has a beta […] - 2025-09-04 02:30:48
Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Hold” at Zacks Research: Zacks Research upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports. Several other analysts also recently weighed in on SUPN. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave […] - 2025-08-22 03:08:51
Maryland State Retirement & Pension System Trims Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Maryland State Retirement & Pension System lessened its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 13.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,094 shares of the specialty pharmaceutical company’s stock after selling 2,514 shares during […] - 2025-08-15 04:51:00
Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 1-Year High on Analyst Upgrade: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report)’s share price hit a new 52-week high on Wednesday after Cantor Fitzgerald raised their price target on the stock from $42.00 to $46.00. Cantor Fitzgerald currently has an overweight rating on the stock. Supernus Pharmaceuticals traded as high as $41.51 and last traded at $42.29, with a […] - 2025-08-08 02:19:00
SUPN Crosses Above Average Analyst Target: In recent trading, shares of Supernus Pharmaceuticals Inc (Symbol: SUPN) have crossed above the average analyst 12-month target price of $40.20, changing hands for $42.44/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down - 2025-08-07 12:32:22
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at Wall Street Zen: Wall Street Zen upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a hold rating to a buy rating in a research note released on Saturday morning. Separately, Cantor Fitzgerald raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $42.00 price objective for the company in a […] - 2025-08-05 02:56:51
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Wall Street Zen: Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday. Supernus Pharmaceuticals Stock Performance Shares of Supernus Pharmaceuticals stock opened at $33.23 on Friday. The firm has a fifty day moving average […] - 2025-07-22 02:55:51
Allspring Global Investments Holdings LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Allspring Global Investments Holdings LLC lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 6.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,353 shares of the specialty pharmaceutical company’s stock after selling 1,356 shares during the quarter. […] - 2025-07-10 04:34:50
Robeco Institutional Asset Management B.V. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Robeco Institutional Asset Management B.V. bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,151 shares of the specialty pharmaceutical company’s stock, valued at approximately $267,000. Other […] - 2025-07-03 05:08:49
Illinois Municipal Retirement Fund Has $927,000 Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Illinois Municipal Retirement Fund decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 2.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,303 shares of the specialty pharmaceutical company’s stock after selling 730 shares […] - 2025-07-02 05:28:54
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stake Boosted by Exchange Traded Concepts LLC: Exchange Traded Concepts LLC increased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 12.5% during the first quarter, HoldingsChannel reports. The firm owned 24,881 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,762 shares during the period. Exchange Traded Concepts LLC’s holdings in Supernus Pharmaceuticals were worth $815,000 at […] - 2025-06-20 05:21:54
Azzad Asset Management Inc. ADV Acquires New Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Azzad Asset Management Inc. ADV acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,847 shares of the specialty pharmaceutical company’s stock, valued at approximately $552,000. A number of other […] - 2025-06-16 05:40:53
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Versant Capital Management Inc: Versant Capital Management Inc grew its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 6,931.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,125 shares of the specialty pharmaceutical company’s stock after purchasing an additional […] - 2025-06-06 05:45:08
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 19,824 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 24.7% during the 4th quarter, Holdings Channel reports. The firm owned 100,020 shares of the specialty pharmaceutical company’s stock after buying an additional 19,824 shares during the period. UBS […] - 2025-06-05 05:10:54
Millennium Management LLC Sells 222,273 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Millennium Management LLC decreased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 87.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,470 shares of the specialty pharmaceutical company’s stock after selling 222,273 shares during […] - 2025-06-05 04:25:01
Squarepoint Ops LLC Sells 475 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Squarepoint Ops LLC cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 2.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 20,492 shares of the specialty pharmaceutical company’s stock after selling 475 shares during the period. Squarepoint Ops LLC’s holdings in Supernus Pharmaceuticals were worth $741,000 at the end of […] - 2025-06-03 05:04:50
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,083 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 3.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 28,563 shares of the specialty pharmaceutical company’s stock after buying an additional 1,083 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Supernus Pharmaceuticals […] - 2025-05-26 04:47:00
Graham Capital Management L.P. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Graham Capital Management L.P. bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,908 shares of the specialty pharmaceutical company’s stock, valued at approximately $250,000. […] - 2025-05-19 05:26:49
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com: StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a research note published on Friday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Get Our Latest Stock […] - 2025-05-19 02:38:47
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Northern Trust Corp: Northern Trust Corp boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 18.3% in the fourth quarter, HoldingsChannel reports. The firm owned 717,161 shares of the specialty pharmaceutical company’s stock after purchasing an additional 110,867 shares during the quarter. Northern Trust Corp’s holdings in Supernus Pharmaceuticals were worth $25,933,000 as […] - 2025-05-12 04:49:02
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP: First Trust Advisors LP lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 48.1% in the 4th quarter, Holdings Channel reports. The firm owned 27,019 shares of the specialty pharmaceutical company’s stock after selling 25,048 shares during the period. First Trust Advisors LP’s holdings in Supernus Pharmaceuticals were worth $977,000 […] - 2025-05-08 04:44:59
Barclays PLC Purchases 14,061 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Barclays PLC increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 12.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 122,849 shares of the specialty pharmaceutical company’s stock after buying an additional 14,061 shares during the period. Barclays PLC’s holdings in Supernus Pharmaceuticals were worth $4,442,000 at […] - 2025-04-28 04:59:03
Raymond James Financial Inc. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Raymond James Financial Inc. bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 189,364 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,847,000. Raymond James Financial Inc. owned approximately […] - 2025-04-24 04:41:05
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Position Raised by Invesco Ltd.: Invesco Ltd. lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 508,069 shares of the specialty pharmaceutical company’s stock after acquiring an additional 22,027 shares during the period. Invesco Ltd. owned 0.92% of […] - 2025-04-20 05:22:48
JPMorgan Chase & Co. Acquires 44,414 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): JPMorgan Chase & Co. grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 17.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 297,810 shares of the specialty pharmaceutical company’s stock after purchasing an additional 44,414 shares during the quarter. […] - 2025-04-15 04:32:48
Arrowstreet Capital Limited Partnership Purchases 77,393 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Arrowstreet Capital Limited Partnership increased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 79.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 174,916 shares of the specialty pharmaceutical company’s stock after acquiring an additional 77,393 shares during […] - 2025-04-08 05:01:05
Prudential Financial Inc. Has $2.37 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Prudential Financial Inc. grew its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 14.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,733 shares of the specialty pharmaceutical company’s stock after buying an additional 8,352 shares […] - 2025-04-04 04:37:01
Sei Investments Co. Sells 16,825 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Sei Investments Co. cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 5.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 296,915 shares of the specialty pharmaceutical company’s stock after selling 16,825 shares during the period. Sei Investments Co.’s holdings in Supernus Pharmaceuticals were worth $10,736,000 at the end of […] - 2025-03-30 05:37:02
Swiss National Bank Has $3.92 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN): Swiss National Bank lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,400 shares of the specialty pharmaceutical company’s stock after purchasing an additional 800 shares during the quarter. […] - 2025-03-26 05:44:46
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com: Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Monday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Get Our Latest […] - 2025-03-26 03:58:55

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) SUPN holdings

Date	Number of SUPN Shares Held	Base Market Value of SUPN Shares	Local Market Value of SUPN Shares	Change in SUPN Shares Held	Change in SUPN Base Value	Current Price per SUPN Share Held	Previous Price per SUPN Share Held
2025-11-11 (Tuesday)	36,699	USD 1,692,191	USD 1,692,191	0	USD 26,056	USD 46.11	USD 45.4
2025-11-10 (Monday)	36,699	USD 1,666,135	USD 1,666,135	94	USD -18,427	USD 45.4	USD 46.02
2025-11-07 (Friday)	36,605	USD 1,684,562	USD 1,684,562	0	USD -45,573	USD 46.02	USD 47.265
2025-11-06 (Thursday)	36,605	USD 1,730,135	USD 1,730,135	94	USD 10,102	USD 47.265	USD 47.11
2025-11-05 (Wednesday)	36,511	USD 1,720,033	USD 1,720,033	0	USD -361,094	USD 47.11	USD 57
2025-11-04 (Tuesday)	36,511	USD 2,081,127	USD 2,081,127	94	USD 52,700	USD 57	USD 55.7
2025-11-03 (Monday)	36,417	USD 2,028,427	USD 2,028,427	0	USD 20,758	USD 55.7	USD 55.13
2025-10-31 (Friday)	36,417	USD 2,007,669	USD 2,007,669	0	USD -49,892	USD 55.13	USD 56.5
2025-10-30 (Thursday)	36,417	USD 2,057,561	USD 2,057,561	470	USD 56,032	USD 56.5	USD 55.68
2025-10-29 (Wednesday)	35,947	USD 2,001,529	USD 2,001,529	188	USD 100,223	USD 55.68	USD 53.17
2025-10-28 (Tuesday)	35,759	USD 1,901,306	USD 1,901,306	0	USD 16,092	USD 53.17	USD 52.72
2025-10-27 (Monday)	35,759	USD 1,885,214	USD 1,885,214	0	USD -3,934	USD 52.72	USD 52.83

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SUPN by Blackrock for IE00BDZVHG35

Show aggregate share trades of SUPN

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 94 45.400* 36.41
2025-11-06 BUY 94 47.265* 36.30
2025-11-04 BUY 94 57.000* 36.13
2025-10-30 BUY 470 57.650 55.170 55.418 USD 26,046 35.81
2025-10-29 BUY 188 55.680 55.945 55.918 USD 10,513 35.70
2025-10-22 SELL -376 50.670 51.470 51.390 USD -19,323 35.23 Loss of -6,076 on sale
2025-10-20 BUY 188 51.590 52.150 52.094 USD 9,794 35.05
2025-10-17 BUY 470 50.170 50.850 50.782 USD 23,868 34.96
2025-10-15 BUY 752 49.270 49.670 49.630 USD 37,322 34.88
2025-10-03 BUY 644 48.350 49.660 49.529 USD 31,897 34.71
2025-10-02 BUY 92 47.960 48.640 48.572 USD 4,469 34.63
2025-09-30 BUY 184 47.790 48.440 48.375 USD 8,901 34.48
2025-09-26 BUY 184 47.030 48.000 47.903 USD 8,814 34.32
2025-09-25 BUY 184 47.180 47.520 47.486 USD 8,737 34.24
2025-09-18 BUY 97 46.130 46.240 46.229 USD 4,484 34.17
2025-09-17 BUY 291 44.800 45.160 45.124 USD 13,131 34.10
2025-09-11 SELL -97 46.660 46.720 46.714 USD -4,531 33.96 Loss of -1,237 on sale
2025-09-10 BUY 194 46.210 46.230 46.228 USD 8,968 33.89
2025-07-17 SELL -194 33.590 34.400 34.319 USD -6,658 33.82 Loss of -96 on sale
2025-07-11 SELL -776 33.120 33.370 33.345 USD -25,876 33.83 Profit of 377 on sale
2025-07-02 BUY 5,335 32.070 32.220 32.205 USD 171,814 33.87
2025-06-25 BUY 194 31.240 31.690 31.645 USD 6,139 33.94
2025-06-20 BUY 819 32.280 33.300 33.198 USD 27,189 33.98
2025-06-13 BUY 832 32.030 32.910 32.822 USD 27,308 34.04
2025-06-11 BUY 184 33.150 33.660 33.609 USD 6,184 34.05
2025-06-10 BUY 184 33.260 33.700 33.656 USD 6,193 34.06
2025-06-04 SELL -92 32.300 32.410 32.399 USD -2,981 34.10 Profit of 156 on sale
2025-04-23 BUY 92 30.840 31.640 31.560 USD 2,904 34.69
2025-04-10 SELL -728 31.070 31.550 31.502 USD -22,933 35.06 Profit of 2,590 on sale
2025-04-08 SELL -91 30.640 33.140 32.890 USD -2,993 35.15 Profit of 205 on sale
2025-04-07 SELL -91 32.270 34.260 34.061 USD -3,100 35.18 Profit of 102 on sale
2025-04-04 SELL -460 32.740 33.350 33.289 USD -15,313 35.21 Profit of 884 on sale
2025-04-01 BUY 380 31.680 32.660 32.562 USD 12,374 35.28
2025-03-31 SELL -276 32.750 32.870 32.858 USD -9,069 35.31 Profit of 677 on sale
2025-03-21 BUY 1,476 32.150 32.900 32.825 USD 48,450 35.54
2025-03-14 SELL -1,392 31.260 31.570 31.539 USD -43,902 35.78 Profit of 5,908 on sale
2025-03-07 SELL -174 32.070 32.300 32.277 USD -5,616 36.08 Profit of 661 on sale
2025-03-04 SELL -87 31.650 31.980 31.947 USD -2,779 36.28 Profit of 377 on sale
2025-02-25 BUY 174 32.810 33.500 33.431 USD 5,817 36.64
2025-02-19 SELL -87 33.520 35.360 35.176 USD -3,060 36.88 Profit of 148 on sale
2025-02-13 BUY 261 39.530 39.540 39.539 USD 10,320 36.68
2025-02-12 BUY 87 38.990 39.490 39.440 USD 3,431 36.63
2025-02-11 BUY 348 38.650 38.660 38.659 USD 13,453 36.59
2024-12-30 SELL -3,233 36.910 37.280 37.243 USD -120,407 35.73 Loss of -4,876 on sale
2024-11-18 SELL -1,425 35.250 36.200 36.105 USD -51,450 34.90 Loss of -1,713 on sale
2024-11-08 SELL -95 36.600 36.780 36.762 USD -3,492 34.57 Loss of -208 on sale
2024-10-21 SELL -96 33.670 34.530 34.444 USD -3,307 0.00 Loss of -3,307 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	94			45.400*		36.41
2025-11-06	BUY	94			47.265*		36.30
2025-11-04	BUY	94			57.000*		36.13
2025-10-30	BUY	470	57.650	55.170	55.418	USD 26,046	35.81
2025-10-29	BUY	188	55.680	55.945	55.918	USD 10,513	35.70
2025-10-22	SELL	-376	50.670	51.470	51.390	USD -19,323	35.23 Loss of -6,076 on sale
2025-10-20	BUY	188	51.590	52.150	52.094	USD 9,794	35.05
2025-10-17	BUY	470	50.170	50.850	50.782	USD 23,868	34.96
2025-10-15	BUY	752	49.270	49.670	49.630	USD 37,322	34.88
2025-10-03	BUY	644	48.350	49.660	49.529	USD 31,897	34.71
2025-10-02	BUY	92	47.960	48.640	48.572	USD 4,469	34.63
2025-09-30	BUY	184	47.790	48.440	48.375	USD 8,901	34.48
2025-09-26	BUY	184	47.030	48.000	47.903	USD 8,814	34.32
2025-09-25	BUY	184	47.180	47.520	47.486	USD 8,737	34.24
2025-09-18	BUY	97	46.130	46.240	46.229	USD 4,484	34.17
2025-09-17	BUY	291	44.800	45.160	45.124	USD 13,131	34.10
2025-09-11	SELL	-97	46.660	46.720	46.714	USD -4,531	33.96 Loss of -1,237 on sale
2025-09-10	BUY	194	46.210	46.230	46.228	USD 8,968	33.89
2025-07-17	SELL	-194	33.590	34.400	34.319	USD -6,658	33.82 Loss of -96 on sale
2025-07-11	SELL	-776	33.120	33.370	33.345	USD -25,876	33.83 Profit of 377 on sale
2025-07-02	BUY	5,335	32.070	32.220	32.205	USD 171,814	33.87
2025-06-25	BUY	194	31.240	31.690	31.645	USD 6,139	33.94
2025-06-20	BUY	819	32.280	33.300	33.198	USD 27,189	33.98
2025-06-13	BUY	832	32.030	32.910	32.822	USD 27,308	34.04
2025-06-11	BUY	184	33.150	33.660	33.609	USD 6,184	34.05
2025-06-10	BUY	184	33.260	33.700	33.656	USD 6,193	34.06
2025-06-04	SELL	-92	32.300	32.410	32.399	USD -2,981	34.10 Profit of 156 on sale
2025-04-23	BUY	92	30.840	31.640	31.560	USD 2,904	34.69
2025-04-10	SELL	-728	31.070	31.550	31.502	USD -22,933	35.06 Profit of 2,590 on sale
2025-04-08	SELL	-91	30.640	33.140	32.890	USD -2,993	35.15 Profit of 205 on sale
2025-04-07	SELL	-91	32.270	34.260	34.061	USD -3,100	35.18 Profit of 102 on sale
2025-04-04	SELL	-460	32.740	33.350	33.289	USD -15,313	35.21 Profit of 884 on sale
2025-04-01	BUY	380	31.680	32.660	32.562	USD 12,374	35.28
2025-03-31	SELL	-276	32.750	32.870	32.858	USD -9,069	35.31 Profit of 677 on sale
2025-03-21	BUY	1,476	32.150	32.900	32.825	USD 48,450	35.54
2025-03-14	SELL	-1,392	31.260	31.570	31.539	USD -43,902	35.78 Profit of 5,908 on sale
2025-03-07	SELL	-174	32.070	32.300	32.277	USD -5,616	36.08 Profit of 661 on sale
2025-03-04	SELL	-87	31.650	31.980	31.947	USD -2,779	36.28 Profit of 377 on sale
2025-02-25	BUY	174	32.810	33.500	33.431	USD 5,817	36.64
2025-02-19	SELL	-87	33.520	35.360	35.176	USD -3,060	36.88 Profit of 148 on sale
2025-02-13	BUY	261	39.530	39.540	39.539	USD 10,320	36.68
2025-02-12	BUY	87	38.990	39.490	39.440	USD 3,431	36.63
2025-02-11	BUY	348	38.650	38.660	38.659	USD 13,453	36.59
2024-12-30	SELL	-3,233	36.910	37.280	37.243	USD -120,407	35.73 Loss of -4,876 on sale
2024-11-18	SELL	-1,425	35.250	36.200	36.105	USD -51,450	34.90 Loss of -1,713 on sale
2024-11-08	SELL	-95	36.600	36.780	36.762	USD -3,492	34.57 Loss of -208 on sale
2024-10-21	SELL	-96	33.670	34.530	34.444	USD -3,307	0.00 Loss of -3,307 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SUPN

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	122,151	3	301,188	40.6%
2025-09-18	121,761	0	267,525	45.5%
2025-09-17	70,393	750	204,211	34.5%
2025-09-16	92,803	0	275,024	33.7%
2025-09-15	117,876	210	292,580	40.3%
2025-09-12	56,904	200	164,689	34.6%
2025-09-11	80,785	50	192,706	41.9%
2025-09-10	97,206	0	247,182	39.3%
2025-09-09	103,403	21,544	214,675	48.2%
2025-09-08	94,030	1,712	217,571	43.2%
2025-09-05	65,260	300	193,611	33.7%
2025-09-04	87,479	9,555	199,603	43.8%
2025-09-03	71,553	1,695	171,333	41.8%
2025-09-02	151,600	32,060	318,698	47.6%
2025-08-29	78,344	2,289	147,467	53.1%
2025-08-28	96,124	974	162,328	59.2%
2025-08-27	98,424	4,105	244,875	40.2%
2025-08-26	68,382	0	134,610	50.8%
2025-08-25	114,093	2,502	258,415	44.2%
2025-08-22	170,458	7,565	320,385	53.2%
2025-08-21	126,877	1,383	256,896	49.4%
2025-08-20	97,552	696	267,866	36.4%
2025-08-19	96,500	5,963	208,444	46.3%
2025-08-18	104,771	1,006	285,510	36.7%
2025-08-15	124,036	20,531	334,977	37.0%
2025-08-14	83,036	4,471	360,725	23.0%
2025-08-13	143,796	4,486	408,810	35.2%
2025-08-12	120,422	909	359,231	33.5%
2025-08-11	112,810	6,919	330,272	34.2%
2025-08-08	228,449	58,762	395,640	57.7%
2025-08-07	334,014	0	923,644	36.2%
2025-08-06	692,071	6,110	1,667,362	41.5%
2025-08-05	248,650	0	476,509	52.2%
2025-08-04	162,989	0	229,997	70.9%
2025-08-01	250,179	0	326,684	76.6%
2025-07-31	433,277	375	912,336	47.5%
2025-07-30	158,360	5	215,826	73.4%
2025-07-29	188,561	0	455,538	41.4%
2025-07-28	160,930	0	241,816	66.6%
2025-07-25	98,853	0	302,328	32.7%
2025-07-24	122,057	0	194,071	62.9%
2025-07-23	62,190	0	125,509	49.6%
2025-07-22	141,516	1,325	343,162	41.2%
2025-07-21	197,089	0	471,962	41.8%
2025-07-18	105,706	0	300,279	35.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE